Briefcases -- Defendants and Defense Counsel -- GSK Qui Tam Transcripts
GSK Qui Tam Transcripts
Case Files
News
Chat
Easy Button
Committees

Categories

  1. Transcripts from GSK Qui Tam 3 Billion Settlement

Documents

  1. Exh 63-Slides-GSK speaker Dr. Pradko’s re-Neuroreceptor Basis-Initial Antidepressant Choice w-ads-audio recording-lecture.pdf
  2. Exhibit 1 GSK performance-based sales incentive-The Strongest Link-Special Incentive Program for Wellbutrin SR.pdf
  3. Exhibit 2 GSK slides providing performance update, market research and 2002 plan of action for Wellbutrin SR.pdf
  4. Exhibit 3 GSK slides-Perceptions and Definition of Antidepressant Efficacy Among PCPs, January 6, 2000.pdf
  5. Exhibit 4 GSK slides-Market Landscape Study-Wellbutrin SR, October 6, 2000.pdf
  6. Exhibit 5 GSK sales training slides-Wellbutrin SR Operation Hustle Meeting May 10 – 18, 1999.pdf
  7. Exhibit 6 GSK sales training material-Insights on Neurotransmitters, August 2000.pdf
  8. Exhibit 7 GSK sales training material Use of Wellbutrin SR for the Treatment of Anxiety – Related Disorders, February 4, 2002.pdf
  9. Exhibit 8 GSK sales training material-Advances in the Treatment of Depression.pdf
  10. Exhibit 9 GSK sales training material comparing Wellbutrin SR to its competition.pdf
  11. Exhibit 10 Newsweek article, How it all Starts Inside Your Brain, as distributed to Wellbutrin field sales teams.pdf
  12. Exhibit 11 Slide set-The Theoretical Role of Dopamine and Norepinephrine in Human Behavior developed by Dr. Jim Hudziak.pdf
  13. Exhibit 12 GSK sales training material- Neurotransmitter and Receptor Pharmacology.pdf
  14. Exhibit 13 GSK slides- Wellbutrin SR- Strategic Plan, April 27, 2000.pdf
  15. Exhibit 14 A. Clayton and J. Pradko, The Prevalence of Sexual Dysfunction Among New – Generation Antidepressants.pdf
  16. Exhibit 15 R. Phillips and J. Slaughter, Depression and Sexual Desire as distributed to GSK Wellbutrin field sales teams.pdf
  17. Exhibit 16 GSK sales training slides- Responding to Physician Questions about Prevalence of Sexual Dysfunction.pdf
  18. Exhibit 17 GSK slides- 2002 Strategy Plan for Wellbutrin SR.pdf
  19. Exhibit 18 Wellbutrin Faxback- Effects of Wellbutrin SR on Body Weight.pdf
  20. Exhibit 19 Glaxo funded study- Bupropion SR in Obesity- A Randomized Double – Blind Placebo – Controlled Study.pdf
  21. Exhibit 20 GSK memo re- New Data on Weight and attachment.pdf
  22. Exhibit 22 -GSK memo re- New Data on Weight and attachment.pdf
  23. Exhibit 24 -GSK 2003 Plan of Action presentation slides showing Wellbutrin’s annual revenue growth.pdf
  24. Exhibit 25 -2003 Wellbutrin Operating Plan.pdf
  25. Exhibit 26 -Wellbutrin SR Memo re- P.R.I.D.E 2001 Program Roll – out.pdf
  26. Exhibit 27 -GSK slide- 2003 PRIDE Rationale & Objectives.pdf
  27. Exhibit 28 -PRIDE Program Schedule – Wellburtrin SR.pdf
  28. Exhibit 29 -Pradko – Hudziak – Green Program Schedule – Wellbutrin SR.pdf
  29. Exhibit 30 -GSK memo re- P.R.I.D.E 2002 Teleconferences – May & June.pdf
  30. Exhibit 31 -Email exchange re- PRIDE Teleconference Slides.pdf
  31. Exhibit 32 -PRIDE Thought Leader Teleconference schedule. February – March 2003.pdf
  32. Exhibit 33 -GSK speaker allocations.pdf
  33. Exhibit 34 -Wellbutrin 2003 Teleconference Schedule.pdf
  34. Exhibit 35 -List of GSK’s approved Wellbutrin PRIDE speakers for 2001.pdf
  35. Exhibit 36 -GSK memo re- 2003 PRIDE Binder.pdf
  36. Exhibit 37 -PRIDE Binder table of contents.pdf
  37. Exhibit 38 -SCS PRIDE program summary.pdf
  38. Exhibit 39 -Wellbutrin SR- Depression Programming listing product speakers by date.pdf
  39. Exhibit 40 -GSK invitation to attend a December 2001 PRIDE event.pdf
  40. Exhibit 43 -Speaker Training Meeting for Wellbutrin SR Agenda for January 26 – 28, 2001, showing Dr. Pradko as a speaker.pdf
  41. Exhibit 44 -Email conversation re- Wellbutrin Teleconference & PRIDE Report(s), May 31, 2002.pdf
  42. Exhibit 45 -Outline from GSK speaker Dr. James Pradko’s presentation Neuroreceptor Basis of Initial Antidepressant Choice.pdf
  43. Exhibit 46-Slides-GSK speaker Dr. James Pradko’s 2-28-02 presentation-Neuroreceptor Basis of Initial Antidepressant Choice.pdf
  44. Exhibit 47-Slides-GSK speaker Dr. James Pradko’s 4-21-02 presentation-Neuroreceptor Basis of Initial Antidepressant Choice.pdf
  45. Exhibit 48-Slides-GSK speaker Dr. James Pradko’s 7-26-02 presentation-Neuroreceptor Basis of Initial Antidepressant Choice.pdf
  46. Exhibit 49-Slides-GSK speaker Dr. James Pradko’s 8-26-02 presentation-Neuroreceptor Basis of Initial Antidepressant Choice.pdf
  47. Exhibit 50-GSK email exchange re- Key Points from Dr. Hudziak Program, August 27, 2002.pdf
  48. Exhibit 51-Slides-GSK speaker Dr. Jim Hudziak’s presents The Theoretical Role of Dopamine & Norepinephrine in Human Behavior.pdf
  49. Exhibit 52-Slides-GSK speaker Dr. Jim Hudziak’s-Theoretical role of Serotonin, Norepinephrine & Dopamine in Human Behavior.pdf
  50. Exhibit 53 -Slides from GSK speaker Dr. Jim Hudziak’s presentation Novel Approaches to the Selection of Antidepressants.pdf
  51. Exhibit 54 -Email exchange re- Key Points from Dr. Hudziak program.pdf
  52. Exhibit 55 -Outline of GSK speaker Dr. Norman Sussman’s September 20, 2002 PRIDE presentation.pdf
  53. Exhibit 56 -Email exchange and summary of a PRIDE event at which GSK speaker Dr. Sarah Atkinson presented.pdf
  54. Exhibit 57-Slides-GSK speaker Dr. Clayton’s presents The Impact Antidepressants have on Sexual Function and Weight.pdf
  55. Exhibit 58 -Slides from a presentation titled Matching the Treatment to the Patient.pdf
  56. Exhibit 59-GSK email fwd notes frm Dr. Atkinson’s PRIDE presentation Mood Disorders in Complex Patients & Overlapping Disorders.pdf
  57. Exhibit 60 -GSK email exchange regarding a PRIDE presentation by Dr. Sarah Atkinson.pdf
  58. Exhibit 61-Slides from GSK speaker Dr. Jeffery Green’s November 1, 2001 presentation Current Issues in Antidepressant Selection.pdf
  59. Exhibit 62-Slides from GSK speaker Dr. Jeffery Green’s Ocotber 29, 2002 presentation Current Issues in Antidepressant Selection.pdf
  60. Exhibit 64-GSK memo re & slides-GSK speaker Dr.Pradko’s March 5, 2000 presents-Neurorecptor Basis-Initial Antidepressant Choice.pdf
  61. Exhibit 65-Wonderful Wellbutrin-article describes Wellbutrin’s sex–enhancing effects-distributed to Wellbutrin field teams.pdf
  62. Exhibit 66 -GSK memo re- New Data on Weight, June 27, 2001.pdf
  63. Exhibit 67 -GSK slides- Effects of Wellbutrin SR on Body Weight.pdf
  64. Exhibit 68 -Slides from GSK speaker Dr. Ken Fujoka’s presentation Effects of Bupropion SR on Body Weight.pdf
  65. Exhibit 69-Slides from a presentation titled Effects of Wellbutrin SR (bupropion HCI) Sustained–Release tablets on Body Weight.pdf
  66. Exhibit 70-Kishore M. Gadde, et al., Bupropion for Weight Loss-Investigation of Efficacy&Tolerability in Overweight&Obese Women.pdf
  67. Exhibit 71-Adesh K. Jain, et al.,-Study-Bupropion SR compared to Placebo in Obese Adults w-Mild to Mod Depressive Symptoms.pdf
  68. Exhibit 72-Results-Glaxo supported studyBupSR Significantly Enhances Weight Loss-Used with Mod–Intense-Lifestyle Intervention.pdf
  69. Exhibit 73 -Gade KM.ParkerCB, ManerLG et al.,Bupro-Weight Loss-investigates of Efficacy&tolerability in Overweight&Obese Women.pdf
  70. Exhibit 74 -GSK Faxback titled Effects of Wellbutrin SR on Body Weight.pdf
  71. Exhibit 75-Slides from presentation-Effects-Wellbutrin SR (bupropion HCI) Sustained Release Tablets-Body Weight.pdf
  72. Exhibit 76 -GSK slides- Bupropion SR for Weight Loss- Combination with SlimFast & Exercise.pdf
  73. Exhibit 77 -Slides from a presentation titled Effects of Wellbutrin SR on Body Weight.pdf
  74. Exhibit 78-GSK faxback titled effects of Wellbutrin SR on Body Weight, February 4, 2002.pdf
  75. Exhibit 79 -Slides-titled Effects of Wellbutrin SR (bupropion HCI) sustained–Release Tablets on Body Weight.pdf
  76. Exhibit 80 -GSK faxback titled Effects of Wellbutrin SR on Body Weight.pdf
  77. Exhibit 81-Slides Dr.Ashton’s titled Decision Making When Managing Antidepressant-Induced Side Effects.pdf
  78. Exhibit 82 -Slide presentation-Effects of Wellbutrin SR (bupropion HCI) Sustained-Release Tablets on Body Weight.pdf
  79. Exhibit 83 -GSK Knowledge Certification scenarios including off – label Wellbutrin weight data.pdf
  80. Exhibit 84 -GSK Wellbutrin SR Knowledge Certification evaluation form.pdf
  81. Exhibit 85-Evaluation form-testing GSK sales rep’s knowledge of Wellbutrin’s off–label treatment-ADHD.pdf
  82. Exhibit 87-GSK slides from 2003 Wellbutrin XL Operating Plan.pdf
  83. Exhibit 88 -GSK operating plan – Activity Phasing Overview.pdf
  84. Exhibit 89 -GSK training slides- Verbalization Review for Valtrex.pdf
  85. Exhibit 90 -GSK marketing slides- Semester I Managers Meeting POA and Update- Valtrex.pdf
  86. Exhibit 91-GSK sponsored study-Tomorrow’s challenges-Herpesvirus Management-Potential Application-Valacyclovir.pdf
  87. Exhibit 92 -GSK training module, Oral Herpes.pdf
  88. Exhibit 93 -GSK memo re- Top 25 Honoraria and Grant Recipients.pdf
  89. Exhibit 94 -GSK’s top ten speakers by product.pdf
  90. Exhibit 95 -Valtrex Monthly NRX – Growth Trac.pdf
  91. Exhibit 96 -GSK’s Peer Discussion Budget, November 2002.pdf
  92. Exhibit 97 -Lamictal Neurology National Speaker List.pdf
  93. Exhibit 98 -Advair Product Information as published August 2000.pdf
  94. Exhibit 99 -Excerpt from GSK Commercial Practices Policies Resource Manual.pdf
  95. Exhibit 100 -Advair Leader Guide- Elion Workshops – Semester I, ’03″.pdf
  96. Exhibit 101 -Avdair Disckus Selling Resource – Semester I – 2003″.pdf
  97. Exhibit 102-Howard Friedman et al., “A Retrospective Study of the Use of Fluticasone Propinate-Salmeterol Combination etc.pdf
  98. Exhibit 103-Transcript-Glaxo-Wellcome presents-Advair Diskus to the FDA Pulmonary&Allergy Drugs Advis. Comm. on 11-23-99.pdf
  99. Exhibit 104 -Medical Officer Review of Advair dated January 24, 2000.pdf
  100. Exhibit 105 -GSK PowerPoint titled Asthma Semester II, 2002.pdf
  101. Exhibit 106 -GSK PowerPoint titled Asthma Promotion 2003 Operating Plan.pdf
  102. Exhibit 107 -Advair marketing materials- Promise Program.pdf
  103. Exhibit 108 -GSK – sponsored Calhoun study.pdf
  104. Exhibit 109 -GSK – sponsored Kavuru study.pdf
  105. Exhibit 111 -Advair sales training material- Advair Selling Resource – Semester I—2003″.pdf
  106. Exhibit 112 -Advair sales training material- Promotional Cycle II – 2004″.pdf
  107. Exhibit 113 -GSK – designed Fuhlbrigge survey.pdf
  108. Exhibit 114 -GSK slides- Asthma Promotion 2003 Operating Plan.pdf
  109. Exhibit 115 -Advair marketing materials.pdf
  110. Exhibit 116 -NIH guidelines for the diagnosis and management of asthma.pdf
  111. Exhibit 117-HHS-NIH 2007 Summary Report-Guidelines for the Diagnosis and Management of Asthma.pdf
  112. Exhibit 118 -Advair product information as published in 2003.pdf
  113. Exhibit 119 -Advair product information as published in 2006.pdf
  114. Exhibit 120 -GSK sales training material- Steroid Sparing Effects of Serevent.pdf
  115. Exhibit 121 -A. McIvor et al., Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma.pdf
  116. Exhibit 123 -GSK letter advising that corticosteroids should not be reduced when salmeterol is initiated.pdf
  117. Exhibit 124 -Advair sales training material- Learning System for Advair Diskus—Unit 3 – Selling Advair Diskus.pdf
  118. Exhibit 125 -FDA – imposed Risk Management Plan.pdf
  119. Exhibit 126 -Adviar Diskus medical officer review (2003).pdf
  120. Exhibit 127 -Flovent Diskus and Advair Diskus 2002 clinical team leader review memorandum (2002).pdf
  121. Exhibit 128 -GSK – sponsored article misrepresenting side effects of Advair 500.pdf
  122. Exhibit 129 -GSK – sponsored article misrepresenting side effects of Advair 500.pdf
  123. Exhibit 130 -GSK faxback incorporating misleading Advair 500 safety information.pdf
  124. Exhibit 131 -GSK faxback incorporating misleading Flovent safety information.pdf
  125. Exhibit 132 -GSK CME Building a COPD Care Plan.pdf
  126. Exhibit 133 -GSK sales training material titled COPD Market Development Selling Resource – Semster II – 2002″.pdf
  127. Exhibit 134 -Adviar Diskus Medical Officer Review (2003).pdf
  128. Exhibit 135 -GSK TORCH study investigating Advair 500 and mortality in COPD patients.pdf
  129. Exhibit 136 -GSK Investor Relations slides delivered by Stan Hull in December 2006.pdf
  130. Exhibit 137 -GSK Investor Relations slides delivered by Stan Hull in June 2006.pdf
  131. Exhibit 138 -GSK Investor Relations slides delivered in February 2007.pdf
  132. Exhibit 139 -GSK Investor Relations slides titled 3Q Results 2006″ listing TORCH as a near – term growth opportunity.pdf
  133. Exhibit 140 -GSK slides showing Advair 500 sales as the fastest growing of any Advair prescription strength.pdf
  134. Exhibit 141 -GSK slides providing Northeast Regional Overview of penetration of GSK prescription drugs.pdf
  135. Exhibit 142 -Imitrex Injection – product information (2001).pdf
  136. Exhibit 143 -Imitrex Nasal Spray – product information (2001).pdf
  137. Exhibit 144 -Imitrex tablets – product information (2000).pdf
  138. Exhibit 145 -Migraine Strategic Plan Review – 2000 – 2004″.pdf
  139. Exhibit 146 -GSK PowerPoint Migraine Brand Review describes expanding the diagnosis for migraine care.pdf
  140. Exhibit 147 -GSK CNS sales materials.pdf
  141. Exhibit 148 -GSK Imitrex sales material using expanded definition of migraine.pdf
  142. Exhibit 149-GSK Market Presentation, OneNerveNetwork–Multiple Presentations-Migraine, stating that Rigid adherence etc.pdf
  143. Exhibit 150 -Imitrex marketing material listing migraine myths.pdf
  144. Exhibit 151 -GSK marketing material- Is it really a tension headache Take a closer look.pdf
  145. Exhibit 152-GSK selling resource suggesting that every headache of a migrianeur is a migraine and could be treated with Imitrex.pdf
  146. Exhibit 153 -GSK marketing material- Physician Diagnosed and Patient Self – Described Sinus Headache is Predominately Migraine.pdf
  147. Exhibit 154 -GSK promotional publication- Issues in Headache Management, February 2003.pdf
  148. Exhibit 155 -GSK promotional materials- Is it really sinus headache Take a closer look.pdf
  149. Exhibit 156-GSK promotional materials explaining Placebo-controlled Study-Migraine patients with self-described ‘sinus headache'.pdf
  150. Exhibit 157 -GSK promotional handout- A Guide to Understanding Your Migraine.pdf
  151. Exhibit 158 -GSK promotional slides- Early Intervention with Imitrex (sumatriptan succinate) in the Treatment of a Migraine Attack.pdf
  152. Exhibit 159 -GSK sales training materials- Central Nervous System Selling Resource, Semester II – 2001″.pdf
  153. Exhibit 160 -GSK documents tracking physician programs and spending in DE County.pdf
  154. Exhibit 161 -GSK documents tracking physician programs and spending in Cherry Hill.pdf
  155. Exhibit 162 -GSK documents tracking physician programs and spending in Wilmington.pdf
  156. Exhibit 163 -GSK sales training slides New GSK Targeting, April 2002.pdf
  157. Exhibit 164 -Documentation of GSK payments to Dr. Jeffrey Green.pdf
  158. Exhibit 165 -Documentation of GSK payments to Dr. Troy Thompson.pdf
  159. Exhibit 166 -Documentation of GSK payments to Dr. Troy Thompson.pdf
  160. Exhibit 167 -Documentation of GSK payments to Dr. James Pradko.pdf
  161. Exhibit 168 -Documentation of GSK payments to Dr. James Pradko.pdf
  162. Exhibit 169 -Documentation of GSK payments to Dr. Matthew Pitera.pdf
  163. Exhibit 170 -Documentation of GSK payments to Dr. Timothy Smith.pdf
  164. Exhibit 171 -Documentation of GSK payments to Dr. James Pradko.pdf
  165. Exhibit 172 -Documentation of GSK payments to physician advisory board speakers.pdf
  166. Exhibit 173 -Documentation of GSK payments to Dr. James Pradko.pdf
  167. Exhibit 174 -Documentation of GSK payments to Dr. Matthew Pitera.pdf
  168. Exhibit 175 -Documentation of GSK payments to Dr. James Hudziak.pdf
  169. Exhibit 176 -Documentation of GSK payments to Dr. James Hudziak.pdf
  170. Exhibit 177 -Documentation of GSK payments to Dr. James Hudziak.pdf
  171. Exhibit 178 -Documentation of GSK payments to Dr. James Pradko.pdf
  172. Exhibit 179 -Documentation of GSK payments to Dr. James Pradko.pdf
  173. Exhibit 180 -Documentation of GSK payments to Dr. James Pradko.pdf
  174. Exhibit 181 -Documentation of GSK payments to Dr. James Hudziak.pdf
  175. Exhibit 182 -Documentation of GSK payments to Dr. James Hudziak.pdf
  176. Exhibit 183 -Documentation of GSK payments to Dr. James Hudziak.pdf
  177. Exhibit 184 -Documentation of GSK payments to Dr. Norman Sussman.pdf
  178. Exhibit 185 -Documentation of GSK payments to Dr. Jeffrey Green.pdf
  179. Exhibit 186 -Documentation of GSK payments to Dr. B. Kenneth Nelson.pdf
  180. Exhibit 187 -Documentation of GSK payments to Dr. James Pradko.pdf
  181. Exhibit 188 -Documentation of GSK payments to Dr. Jeffrey Green.pdf
  182. Exhibit 189 -Documentation of GSK payments to Dr. James Pradko.pdf
  183. Exhibit 190 -Documentation of GSK payments to Dr. James Hudziak.pdf
  184. Exhibit 191 -Documentation of GSK payments to Dr. James Hudziak.pdf
  185. Exhibit 192 -Documentation of GSK payments to Dr. James Hudziak.pdf
  186. Exhibit 193 -Documentation of GSK payments to Dr. James Pradko.pdf
  187. Exhibit 194 -Documentation of GSK payments to Dr. James Hudziak.pdf
  188. Exhibit 195 -GSK Special Issue Boards Schedule.pdf
  189. Exhibit 196 -GSK slides evaluating luxury boxes and season tickets expenses.pdf
  190. Exhibit 197 -GSK documents tracking physician programs and spending in Harrisburg.pdf
  191. Exhibit 198 -GSK documents tracking physician programs and spending in Lancaster.pdf
  192. Exhibit 199 -GSK documents tracking physician programs and spending in West Chester.pdf
  193. Exhibit 200 -GSK documents tracking physician programs and spending in Camp Hill.pdf
  194. Exhibit 201 -Outline from GSK speaker Dr. Sarah Atkinson’s presentation on mood disorders.pdf
  195. Exhibit 202 -GSK physician tutorial schedule.pdf
  196. Exhibit 203 -GSK documents tracking physician programs and spending in Roxborough.pdf
  197. Exhibit 205 -GSK documents tracking physician programs and spending in Lehigh Valley.pdf
  198. Exhibit 206 -GSK email exchange Re Grant Request for Dr. London, May 9, 2002.pdf
  199. Exhibit 207 -GSK email exchange Re WSR Materials, May 24, 2002.pdf
  200. Exhibit 208 -GSK email exchange Re Profiles and Depression – CME, July 16, 2002.pdf
  201. Exhibit 209 -GSK slides explaining 2002 Imitrex marketing and speaker programs.pdf
  202. Exhibit 210 -Letter confirming James Pradko’s GSK speaking commitments.pdf
  203. Exhibit 211 -GSK’s Top Ten speakers by product.pdf
  204. Exhibit 212 -GSK email exchange re- Dr. Sussman’s Buffalo Programs on 9-20-02, August 7, 2002.pdf
  205. Exhibit Names.docx
  206. GSK Settlement Agreement.pdf
  207. Settlement_Fact_Sheet.pdf
  208. GSK Settlement Agreement.pdf
  209. glaxowhistleblowers____ettlement_agreement_pdf.docx
  210. glaxowhistleblowers____ettlement_agreement_pdf.pdf
  211. glaxo-settlement-agreement.pdf
  212. GSK Qui Tam Complaint.pdf
  213. US-vs.GSK-7th-Amended-Complaint.pdf
  214. GlaxoSmithKline whistleblower speaks out about bribery of doctors, off-label marketing of drugs.mp4
  215. Whistleblower Attorney Erika Kelton Discusses GSK Kickbacks.mp4
View All

Discussion

    No Recent Messages
Add Comment